Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Metastatic Lung Adenocarcinoma: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Metastatic Lung Adenocarcinoma: 1 US clinical trial tracked, none currently recruiting.

Metastatic Lung Adenocarcinoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Alliance for Clinical Trials in Oncology, running 1 of these trials.

Enrollment posture brief

Registry condition metastatic-lung-adenocarcinoma

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Metastatic Lung Adenocar (th…0%
Open-enrollment share among volume-matched conditions near Metastatic Lung Adenocarcinoma

Metastatic Lung Adenocarcinoma has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Metastatic Lung Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Metastatic Lung Adenocarcinoma is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Metastatic Lung Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Comprehensive Geriatric Assessment Other
1 trials
Questionnaire Administration Other
1 trials
Pemetrexed Drug
1 trials
Carboplatin Drug
1 trials
Pembrolizumab Drug
1 trials

US sites by state

Facility locations filed on Metastatic Lung Adenocarcinoma trials. A trial with sites in several states counts in each.

Colorado 1 trials
California 1 trials
Arizona 1 trials
Alaska 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Metastatic Lung Adenocarcinoma page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Lung Adenocarcinoma condition card totals 1 registered trials; most-linked intervention Comprehensive Geriatric Assessment; top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.